 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 September 1997 | Volume 127 Issue 5 | Pages 337-345
Background: The effect of angiotensin-converting enzyme (ACE) inhibitors in slowing the decline in renal function in nondiabetic renal disease varies among studies.
Purpose: To use meta-analysis to assess the effect of ACE inhibitors on the development of end-stage renal disease caused by factors other than diabetes.
Data Sources: The English-language medical literature, identified by a MEDLINE search, and unpublished studies.
Study Selection: All randomized studies that compared ACE inhibitors with other antihypertensive agents and had at least 1 year of planned follow-up were selected. Studies of diabetic renal disease and renal transplants were excluded. A total of 1594 patients in 10 studies was included.
Data Extraction: Data on end-stage renal disease, death, drop out, and blood pressure were extracted. Study investigators confirmed results and provided additional data.
Data Synthesis: Among 806 patients receiving ACE inhibitors, 52 (6.4%) developed end-stage renal disease and 17 (2.1%) died; in the 788 controls, the respective values were 72 (9.1%) and 12 (1.5%). The pooled relative risks were 0.70 (95% CI, 0.51 to 0.97) for end-stage renal disease and 1.24 (CI, 0.55 to 2.83) for death; the studies were not significantly heterogeneous. The decreases in weighted mean systolic and diastolic blood pressures during follow-up were 4.9 and 1.2 mm Hg greater, respectively, in the patients who received ACE inhibitors.
Conclusions: Angiotensin-converting enzyme inhibitors are more effective than other antihypertensive agents in reducing the development of end-stage nondiabetic renal disease, and they do not increase mortality. It could not be determined whether this beneficial effect is due to the greater decline in blood pressure or to other effects of ACE inhibition.
Author and Article Information
For the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group*
ARTICLE
Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease
A Meta-Analysis of Randomized Trials
From New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
*For members of the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, see Appendix.
Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996; 7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group [16] has been published (Lancet. 1997; 349:1857-63); this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death.
Acknowledgments: The following companies provided support for the individual studies cited in these analyses: Merck Sharp & Dohme (Denmark, France, the Netherlands, and the United States), Merck & Co., Inc. (Australia). Roche AB (Sweden). Ciba-Geigy (Italy), and Bayer Australia. The authors thank Dr. John Ioannides, who assisted in statistical analysis.
Grant Support: In part by awards R01 HS07782 and R01 HS08532 from the Agency for Health Care Policy and Research of the U.S. Public Health Service.
Requests for Reprints: Andrew S. Levey. MD, Division of Nephrology, Department of Medicine, New England Medical Center, 750 Washington Street, NEMC# 391, Boston, MA 02111.
Current Author Addresses: Drs. Levey and Giatras: Division of Nephrology, Department of Medicine, New England Medical Center, 750 Washington Street, NEMC# 391, Boston, MA 02111.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. G. Craig and J. M. Hunter Recent developments in the perioperative management of adult patients with chronic kidney disease Br. J. Anaesth., September 1, 2008; 101(3): 296 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Garg, D. Hackam, and M. Tonelli Systematic Review and Meta-analysis: When One Study Is Just not Enough Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 253 - 260. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gao, B. J. Manns, B. F. Culleton, M. Tonelli, H. Quan, L. Crowshoe, W. A. Ghali, L. W. Svenson, B. R. Hemmelgarn, and for the Alberta Kidney Disease Network Prevalence of Chronic Kidney Disease and Survival among Aboriginal People J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2953 - 2959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. M. Saweirs and J. Goddard What are the best treatments for early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix31 - ix38. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bang, S. Vupputuri, D. A. Shoham, P. J. Klemmer, R. J. Falk, M. Mazumdar, D. Gipson, R. E. Colindres, and A. V. Kshirsagar SCreening for Occult REnal Disease (SCORED): A Simple Prediction Model for Chronic Kidney Disease Arch Intern Med, February 26, 2007; 167(4): 374 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hiramatsu, K. Hiromura, T. Shigehara, T. Kuroiwa, H. Ideura, N. Sakurai, S. Takeuchi, M. Tomioka, H. Ikeuchi, Y. Kaneko, et al. Angiotensin II Type 1 Receptor Blockade Inhibits the Development and Progression of HIV-Associated Nephropathy in a Mouse Model J. Am. Soc. Nephrol., February 1, 2007; 18(2): 515 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-y. Hsu and H. I. Feldman Clinical Research Methods in CJASN Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1115 - 1116. [Full Text] [PDF]
|
|
|
|
|
|
C. Jacobs Costs and benefits of improving renal failure treatment--where do we go? Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2049 - 2052. [Full Text] [PDF]
|
|
|
|
|
|
Y. Kanno, T. Takenaka, T. Nakamura, and H. Suzuki Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 730 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Jacobsen Preventing end stage renal disease in diabetic patients -- genetic aspect (part I) Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 1 - 14. [Abstract] [PDF]
|
|
|
|
|
|
C. Chiurchiu, G. Remuzzi, and P. Ruggenenti Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S58 - S63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Chrysant and G. S. Chrysant Pharmacological and Clinical Profile of Moexipril: A Concise Review J. Clin. Pharmacol., August 1, 2004; 44(8): 827 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Winkelmayer, R. Kewalramani, M. Rutstein, S. Gabardi, T. Vonvisger, and A. Chandraker Pharmacoepidemiology of Anemia in Kidney Transplant Recipients J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1347 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Samson Hypertension and the Vascular Patient Vascular and Endovascular Surgery, March 1, 2004; 38(2): 103 - 119. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Suzuki, T. Yamamoto, N. Ikegaya, and A. Hishida Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression Am J Physiol Renal Physiol, February 1, 2004; 286(2): F267 - F277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Wilmer, B. H. Rovin, C. J. Hebert, S. V. Rao, K. Kumor, and L. A. Hebert Management of Glomerular Proteinuria: A Commentary J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3217 - 3232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Flack, R. Peters, T. Shafi, H. Alrefai, S. A. Nasser, and E. Crook Prevention of Hypertension and Its Complications: Theoretical Basis and Guidelines for Treatment J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tu, M. M. Mamdani, R. M. Jacka, N. J. Forde, D. M. Rothwell, and J. V. Tu The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario Can. Med. Assoc. J., March 4, 2003; 168(5): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pilote Ramipril use in Canada: HOPE or HYPE? Can. Med. Assoc. J., March 4, 2003; 168(5): 568 - 569. [Full Text] [PDF]
|
|
|
|
|
|
A. Stanton Review: Potential of renin inhibition in cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 6 - 10. [Abstract] [PDF]
|
|
|
|
|
|
J. Segura, M. Praga, C. Campo, J. L Rodicio, and L. M Ruilope Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 43 - 47. [Abstract] [PDF]
|
|
|
|
|
|
M. Tonelli, J. Gill, S. Pandeya, C. Bohm, A. Levin, and B. A. Kiberd Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1426 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Swales and B. Williams Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 79 - 89. [Abstract] [PDF]
|
|
|
|
|
|
H. Bos, R. H. Henning, P. E. de Jong, D. de Zeeuw, and G. Navis Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition? Nephrol. Dial. Transplant., May 1, 2002; 17(5): 793 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Clase, A. X. Garg, and B. A. Kiberd Prevalence of Low Glomerular Filtration Rate in Nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III) J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1338 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Remuzzi, P. Ruggenenti, and N. Perico Chronic Renal Diseases: Renoprotective Benefits of Renin-Angiotensin System Inhibition Ann Intern Med, April 16, 2002; 136(8): 604 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jungers Late referral: loss of chance for the patient, loss of money for society Nephrol. Dial. Transplant., March 1, 2002; 17(3): 371 - 375. [Full Text] [PDF]
|
|
|
|
|
|
T. Hannedouche, J. Chanard, B. Baumelou, and French Collaborative Telmisartan Study Group Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 246 - 254. [Abstract] [PDF]
|
|
|
|
|
|
P. Ruggenenti, A. Perna, and G. Remuzzi ACE Inhibitors to Prevent End-Stage Renal Disease: When to Start and Why Possibly Never to Stop: A Post Hoc Analysis of the REIN Trial Results J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2832 - 2837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Herlitz, K. Harris, T. Risler, G. Boner, J. Bernheim, J. Chanard, and M. Aurell The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2158 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Segura, C. Campo, J. L. Rodicio, and L. M. Ruilope ACE Inhibitors and Appearance of Renal Events in Hypertensive Nephrosclerosis Hypertension, September 1, 2001; 38(3): 645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Jafar, C. H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B. M. Brenner, A. Kamper, P. Zucchelli, et al. Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data Ann Intern Med, July 17, 2001; 135(2): 73 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. KAUSZ, S. S. KHAN, R. ABICHANDANI, W. H. KAZMI, G. T. OBRADOR, R. RUTHAZER, and B. J. G. PEREIRA Management of Patients with Chronic Renal Insufficiency in the Northeastern United States J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1501 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Toto Angiotensin II Subtype 1 Receptor Blockers and Renal Function Arch Intern Med, June 25, 2001; 161(12): 1492 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Schmid Using Bayesian Inference to Perform Meta-Analysis Eval Health Prof, June 1, 2001; 24(2): 165 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 Lowering blood pressure in particular patient groups DTB, May 1, 2001; 39(5): 37 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Rump, K. Amann, S. Orth, and E. Ritz Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol. Dial. Transplant., November 1, 2000; 15(11): 1735 - 1738. [Full Text] [PDF]
|
|
|
|
|
|
B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER Recommendations for the Outpatient Surveillance of Renal Transplant Recipients J. Am. Soc. Nephrol., October 1, 2000; 11(2007): S1 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wright Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 3: Angiotensin-converting-enzyme inhibitors Can. Med. Assoc. J., August 1, 2000; 163(3): 293 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Grossman, F. H. Messerli, and J. M. Neutel Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors? Arch Intern Med, July 10, 2000; 160(13): 1905 - 1911. [Full Text] [PDF]
|
|
|
|
|
|
W. J. Elliott, D. R. Weir, and H. R. Black Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients Arch Intern Med, May 8, 2000; 160(9): 1277 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Mange, B. Cizman, M. Joffe, and H. I. Feldman Arterial Hypertension and Renal Allograft Survival JAMA, February 2, 2000; 283(5): 633 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C R V Tomson Recent advances: Nephrology BMJ, January 8, 2000; 320(7227): 98 - 101. [Full Text]
|
|
|
|
|
|
A. Fournier, A. Pruna, N. E. Esper, R. Makdassi, R. Oprisiu, P.-F. Westeel, H. Mazouz, and J.-M. Achard Captopril prevention project--what shall we do about captopril and the risk of stroke? Nephrol. Dial. Transplant., January 1, 2000; 15(1): 2 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Frohlich The necessity for recognition and treatment of patients with "mild" hypertension J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1369 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. LEVEY, T. GREENE, G. J. BECK, A. W. CAGGIULA, J. W. KUSEK, L. G. HUNSICKER, and S. KLAHR Dietary Protein Restriction and the Progression of Chronic Renal Disease: What Have All of the Results of the MDRD Study Shown? J. Am. Soc. Nephrol., November 1, 1999; 10(11): 2426 - 2439. [Abstract] [Full Text]
|
|
|
|
|
|
P. Jungers Screening for renal insufficiency: is it worth while? is it feasible? Nephrol. Dial. Transplant., September 1, 1999; 14(9): 2082 - 2084. [Full Text] [PDF]
|
|
|
|
 |
|
 A.M. El-Nahas and N. Tamimi The progression of chronic renal failure: a harmful quartet QJM, August 1, 1999; 92(8): 421 - 424. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Moore, M. Epstein, L. Agodoa, and L. D. Dworkin Current Strategies for Management of Hypertensive Renal Disease Arch Intern Med, January 11, 1999; 159(1): 23 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Dooley and R J Falk Immunosuppressive therapy of lupus nephritis Lupus, November 1, 1998; 7(9): 630 - 634. [Abstract] [PDF]
|
|
|
|
|
|
M. Rahman and M. C. Smith Chronic Renal Insufficiency: A Diagnostic and Therapeutic Approach Arch Intern Med, September 14, 1998; 158(16): 1743 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and endorsed by the British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice Heart, July 1, 1998; 80(90002): 1S - 29. [Full Text]
|
|
|
|
 |
|
 ACE INHIBITORS DELAY END-STAGE RENAL DISEASE Journal Watch (General), September 12, 1997; 1997(912): 1 - 1. [Full Text]
|
|
Article
